ClinicalTrials.gg
Active, not recruitingNCT06095115ICONIC-LEADUpdated Nov 4, 2026Results posted

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of JNJ-77242113 and Placebo in Plaque Psoriasis, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 170 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Nov 4, 20264 sites added4 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
684
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Psoriasis by Johnson & Johnson — 3 open to participants now, 12 under way, 7 of them phase 3. Psoriasis · Johnson & Johnson.

Enrollment
12th of 58
684 · median 222
Started
2023
with 2 others
Phase 3
36 of 76
none open now
Primary completion
2024-07
later than 2 of 11 live
Registered
67th of 76
by date

Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 12th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2023, is one of 36 in phase 3, reaches primary completion later than 2 of the 11 other live ones, and was the 67th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 76 studies in Psoriasis by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Psoriasis by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of plaque psoriasis, with or without psoriatic arthritis, for at least 26 weeks prior to the first administration of study intervention
  • Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
  • Total psoriasis area and severity index (PASI) >=12 at screening and baseline
  • Total investigator global assessment (IGA) >=3 at screening and baseline
  • Candidate for phototherapy or systemic treatment for plaque psoriasis
  • A female participant of must have a negative highly sensitive serum pregnancy test beta-human chorionic gonadotropin (beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention

Exclusion criteria

Exclusion Criteria:

  • Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
  • Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  • Known allergies, , or intolerance to JNJ-77242113 or its
  • Major surgical procedures, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from a surgical procedure or has a surgical procedure planned during the time the participant is expected to participate in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
684 participants (actual)

Study arms

  • Experimental
    JNJ-77242113

    Adolescent and adult participants will receive JNJ-77242113 from Week 0 through Week 156. At Week 24, adult participants who are psoriasis area and severity index (PASI) 75 or investigator global assessment (IGA) score of 0 or 1 responders (that is, those who achieve an IGA score of 0 or 1 and have \>=2-grade improvement from baseline) will be re-randomized either to continue JNJ-77242113 or to placebo (and will be retreated with JNJ-77242113 upon loss of \>=50% of their Week 24 PASI improvement). Adult participants identified as both PASI 75 and IGA 0 or 1 score non-responders will continue to receive JNJ-77242113 through Week 52. From Week 52 to Week 156, all adult participants will receive JNJ-77242113. Adolescents will not participate in re-randomization regardless of their PASI score or IGA score at Week 24. Adolescents will continue to receive JNJ-77242113 from Week 0 through Week 156.

    Drug: JNJ-77242113

  • Experimental
    Placebo

    Adolescent and adult participants will receive JNJ-77242113 matching placebo from Week 0 to Week 16. Participants will cross-over to receive JNJ-77242113 from Week 16 through Week 156.

    Drug: JNJ-77242113 · Drug: Placebo

Interventions

  • JNJ-77242113 will be administered orally.

  • DrugPlacebo

    Placebo will be administered orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16

    IGA assesses participant's plaque psoriasis.Lesions were graded for induration,erythema and scaling, each using 5 point scale.Induration: 0=no evidence of plaque elevation,1=minimal plaque elevation,=0.25 millimeters(mm);2=mild plaque elevation,=0.5mm;3=moderate plaque elevation,=0.75 mm; 4=severe plaque elevation, greater than(\>)1 mm; Erythema:0=no evidence of erythema, hyperpigmentation may be present,1=faint erythema,2=light red coloration,3=moderate red coloration,4=bright red coloration; Scaling:0=no evidence of scaling, 1=minimal; occasional fine scale over \<5% of lesion, 2=mild; fine scale dominates,3=moderate; coarse scale predominates, 4=severe; thick, scale predominates. Final IGA score of psoriasis was based upon average of induration, erythema and scaling scores assessed on a 5 point scale:cleared(0),minimal(1), mild(2),moderate(3),or severe(4). Higher score=more severe disease. Baseline:closest measurement taken prior to or at time of first study drug administration date.

    Time frame: Week 16

  2. Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

    Percentage of participants who achieved PASI 90 (at least 90% improvement from baseline in PASI score) response at Week 16 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved IGA Score of 0 at Week 16

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeter (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

    Time frame: Week 16

  2. Percentage of Participants Who Achieved PASI 75 Response at Week 4

    Percentage of participants who achieved PASI 75 (at least \>=75% improvement from baseline in PASI) response at Week 4 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 4

  3. Percentage of Participants Who Achieved PASI 90 Response at Week 8

    Percentage of participants who achieved PASI 90 (at least \>=90% improvement from baseline in PASI) response at Week 8 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 8

  4. Percentage of Participants Who Achieved PASI 75 Response at Week 16

    Percentage of participants who achieved PASI 75 (\>=75% improvement from baseline in PASI) response at Week 16 were reported.. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  5. Percentage of Participants Who Achieved PASI 100 Response at Week 16

    Percentage of participants who achieved PASI 100 (100% improvement from baseline in PASI) response at Week 16 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  6. Percentage of Participants Who Achieved Scalp Specific (ss)-IGA Score of 0 or 1 and >=2-Grade Improvement From Baseline at Week 16 Among Participants With a Baseline Ss-IGA Score >=2

    The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions were assessed in terms of the clinical signs of redness, thickness, and scaliness, which are scored on a 5-point scale ranging from 0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, and 4 = severe disease. Higher score indicated severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  7. Percentage of Participants Who Achieved Psoriasis Symptom and Signs Diary (PSSD) Symptom Score of 0 at Week 8 Among Participants With a Baseline PSSD Symptom Score >0

    PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Symptom score was derived first by averaging the 5 weekly symptom item scores when at least 3 items are available (\>=50% of 5 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 8

  8. Percentage of Participants Who Achieved Psoriasis Symptom and Signs Diary (PSSD) Symptom Score of 0 at Week 16 Among Participants With a Baseline PSSD Symptom Score >0

    PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Symptom score was derived first by averaging the 5 weekly symptom item scores when at least 3 items are available (\>=50% of 5 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  9. Percentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Week 4 Among Participants With a Baseline PSSD Itch Score >=4

    PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms(itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. PSSD itch item score over seven days was averaged into a weekly itch score, ranging from 0 to 10 with higher scores indicating severe disease. Baseline=closest measurement taken prior to or at time of first study drug administration date.

    Time frame: Week 4

  10. Percentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Week 16 Among Participants With a Baseline PSSD Itch Score >=4

    PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms(itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. PSSD itch item score over seven days was averaged into a weekly itch score, ranging from 0 to 10 with higher scores indicating severe disease. Baseline=closest measurement taken prior to or at time of first study drug administration date.

    Time frame: Week 16

  11. Percentage of Participants Who Achieved PASI 75 Response at Week 52 Among Participants Randomized at Week 24 and Were PASI 75 Responders at Week 24

    Percentage of participants who achieved PASI-75 score (\>=75% improvement from baseline in PASI) at Week 52 among participants randomized at Week 24 and were PASI 75 responders at Week 24 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. Baseline=closest measurement taken prior to or at time of first study drug administration date.

    Time frame: Week 52

  12. Percentage of Participants Who Achieved PASI 90 Response at Week 52 Among Participants Randomized at Week 24 and Were PASI 90 Responders at Week 24

    Percentage of participants who achieved PASI 90 (at least \>=90% improvement from baseline in PASI) response at Week 52 among participants randomized at Week 24 and were PASI 90 responders at Week 24 were reported. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. Baseline=closest measurement taken prior to or at time of first study drug administration date.

    Time frame: Week 52

  13. Time to Loss of PASI 75 Among Participants Randomized at Week 24 and Were PASI 75 Responders at Week 24

    Time to loss of PASI 75 response was defined as time from re-randomization at Week 24 to visit of loss of PASI 75 response. Loss of PASI 75 response was defined as less than (\<)75% improvement in PASI from Week 24 up to Week 52 in an adult participant who had achieved \>=75% improvement in PASI from baseline at Week 24. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis.

    Time frame: Week 24 up to Week 52

  14. Time to Loss of PASI 90 Among Participants Randomized at Week 24 and Were PASI 90 Responders at Week 24

    The time to loss of PASI 90 response was defined as the time from re-randomization at Week 24 to the visit of loss of PASI 90 response. Loss of PASI 90 response is defined as \<90% improvement in PASI from Week 24 up to Week 52 in an adult participant who had achieved \>=90% improvement in PASI from baseline at Week 24. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis.

    Time frame: Week 24 up to Week 52

  15. Change From Baseline in Body Surface Area (BSA) at Week 16

    A BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using hand print method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1% BSA. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  16. Change From Baseline in PASI Total Score at Week 16

    Change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  17. Percent Change From Baseline in PASI Total Score at Week 16

    Percent change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  18. Percentage of Participants Who Achieved Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 and a >=2-Grade Improvement in Genital Psoriasis From Baseline at Week 16 Among Participants With a Baseline sPGA-G Score >=2

    Percentage of participants achieving a sPGA-G Score of 0 or 1 and at least a 2-grade improvement in genital psoriasis from baseline at Week 16 among participants with a baseline sPGA-G score \>=2 was reported. The sPGA-G was a 6-point scale to assess the severity of genital psoriasis at a given time point. The sPGA-G evaluates erythema, plaque elevation, and scale of genital psoriatic lesions. The severity of genital psoriasis was assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), and very severe (5). Higher score indicates more severity. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  19. Percentage of Participants Achieving a Physician's Global Assessment of Hands and Feet (Hf-PGA) Score of 0 or 1 and at Least a 2-grade Improvement at Week 16 Among Participants With a Baseline Hf-PGA Score >=2

    Percentage of participants achieving a hf-PGA score of 0 or 1 and at least a 2-grade improvement at Week 16 among participants with a baseline hf-PGA score \>=2 was reported. The hf-PGA assesses the severity of hand and foot psoriasis using a 5-point scale to score the plaques on the hands and feet. hf-PFA was categorized from 0 to 4 where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Higher score indicates more severity. Meeting the hf-PGA 0 or 1 criteria defined as having an hf-PGA score of clear (0) or almost clear (1) and a \>=2-grade improvement from baseline. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  20. Percent Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 16 Among Participants With Baseline mNAPSI Score >0

    The mNAPSI was an index used for assessing and grading the severity of nail psoriasis. Each of the participant's ten fingernails are evaluated on 7 features. The first three features are each scored from 0 to 3 in severity and were 1 = onycholysis and oil-drop dyschromia, 2 = pitting, and 3 = nail plate crumbling. The next four features was each scored 0 (absent) or 1 (present), and are (1) leukonychia, (2) splinter hemorrhages (3) nail bed hyperkeratosis, and (4) red spots in the lunula. Each fingernail is rated for the presence and severity of seven features to give a total fingernail score of 0-13 (0= no involvement, 13 = greatest involvement). The total mNAPSI score is the sum of the 10 fingernail scores (range 0-130; 0= no involvement, 130= greatest involvement). The higher the score the more severe the nail bed psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  21. Percentage of Participants Who Achieved Fingernail Physician's Global Assessment (f-PGA) Score of 0 or 1 at Week 16 Among Participants With a Baseline f-PGA Score >=2

    Percentage of participants who achieved f-PGA score of 0 or 1 at Week 16 was reported. f-PGA 0 or 1 criteria was defined as an f-PGA score of clear (0) or minimal (1). The f-PGA is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe. The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4= severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  22. Change From Baseline in PSSD Symptom Score at Week 16

    PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms(itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Symptom score was derived by averaging the 5 weekly symptom item scores when at least 3 items are available (\>=50% of 5 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  23. Change From Baseline in PSSD Sign Score at Week 16

    PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms(itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Sign score was derived by averaging the 6 weekly sign item scores when at least 3 items are available (\>=50% of 6 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  24. Percentage of Participants Achieving PSSD Sign Score of 0 at Week 16 Among Participants With Baseline PSSD Sign Score >0

    PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Sign score was derived by averaging the 6 weekly sign item scores when at least 3 items are available (\>=50% of 6 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  25. Percentage of Participants Achieving Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16 Among Participants With Baseline GenPS-SFQ Item 2 Score >=2 and a Baseline sPGA-G Score >=3

    Percentage of participants achieving GenPs-SFQ Item 2 score of 0 or 1 at Week 16 among participants with baseline GenPS-SFQ Item 2 score \>=2 and a baseline sPGA-G score \>=3 was reported. GenPs-SFQ was a 2-item participant-reported instrument used to assess the impact of genital psoriasis on the frequency of sexual activity in the last 7 days. Item 1 assesses overall frequency of sexual activity in the last 7 days (none/ zero, once, or 2 or more times), and item 2 assesses how frequently genital psoriasis symptoms have limited the frequency of sexual activity in the last 7 days (0 = never, 1 = rarely, 2 = sometimes, 3 = often, or 4 = always). Lower scores of item 2 indicated less limitation of sexual activity due to genital psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  26. Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16 Among Participants With a Baseline DLQI Score >1

    The DLQI was a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It was a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, could be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Each question was scored on a 4-point scale of 0 to 3 (0 = not at all, 1 = a little; 2 = a lot; or 3 = very much, where higher score indicated more impact on QoL). The total score was sum of scores from all 10 questions and it ranged from 0 (not at all) to 30 (very much), with a higher score indicating greater impact on HRQoL. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  27. Change From Baseline in Total DLQI Score at Week 16

    Change from baseline in total DLQI score at Week 16 was reported. The DLQI was a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It was a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, could be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Each question was scored on a 4-point scale of 0 to 3 (0 = not at all, 1 = a little; 2 = a lot; or 3 = very much, where higher score indicated more impact on QoL). The total score was sum of scores from all 10 questions and it ranged from 0 (not at all) to 30 (very much), with a higher score indicating greater impact on HRQoL. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  28. Adult Participants: Change From Baseline in Domain Scores of the Patient-reported Outcomes Measurement Information System-29 (PROMIS-29) Score at Week 16

    PROMIS-29, 29-item generic HRQoL survey, assesses each 7 PROMIS domains (depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; ability to participate in social roles and activities) with 4 questions and pain intensity. Questions ranked on 5-point Likert Scale (1=never, 2=rarely, 3=sometimes, 4=often and 5=always). Pain intensity was rated on 11-point scale (0=no pain; 10=worst imaginable pain). Higher score= worst pain. Each domain included 4 items, plus a single pain intensity item totaling 29 items. Raw score of each PROMIS domain was converted into a standardized score with mean of 50; standard deviation (SD) of 10 (T-Score). Higher PROMIS T score=more of concept being measured that is, higher scores in anxiety, depression, fatigue, pain interference, sleep disturbance= worse symptoms, higher scores in physical function, social roles=better functioning. Baseline: closest measurement taken prior to/at the time of first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  29. Adolescent Participants: Percentage of Participants Achieving Children's Dermatology Life Quality Index (CDLQI) Score of 0 or 1 at Week 16 Among Participants With a Baseline CDLQI Score >1

    The CDLQI was an adapted version of the DLQI for the pediatric population and was utilized in the adolescent population in this study. The CDLQI is a 10-item instrument that has 4 item response options and a recall period of 1 week. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of questions 1-10 and ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children. The instrument is designed for use in children, is self-explanatory and can be simply handed to the participant who asked to fill it in with the help of the child's parent or caregiver. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Week 16

  30. Adolescent Participants: Change From Baseline in CDLQI at Week 16

    The CDLQI was an adapted version of the DLQI for the pediatric population and was utilized in the adolescent population in this study. The CDLQI is a 10-item instrument that has 4 item response options and a recall period of 1 week. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of questions 1-10 and ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children. The instrument is designed for use in children, is self-explanatory and can be simply handed to the participant who asked to fill it in with the help of the child's parent or caregiver. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  31. Adolescent Participants: Change From Baseline in Domain Scores of the PROMIS-25 Pediatric Score at Week 16

    The PROMIS-25 was utilized in the adolescent population and is a 25-item generic HRQoL survey. Six PROMIS domains (physical function mobility, anxiety, depressive symptoms, fatigue, peer relationships, pain interference) are each assessed with 4 questions. Questions ranked on 5-point Likert Scale (1=never, 2=rarely, 3=sometimes, 4=often, 5=always). Higher score=worst pain. Raw scores for each domain were converted to T-scores using standardized score with a mean of 50 and a standard deviation (SD) of 10 with an observed range 20 to 80. For anxiety, depressive symptoms, fatigue, and pain interference, a negative change indicates an improvement while for physical function mobility and peer relationships, a positive change indicates an improvement. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  32. Percentage of Participants Who Achieved an IGA Score of 0 or 1 and >=2-Grade Improvement From Baseline at Week 52

    IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0=no evidence of plaque elevation, 1=minimal plaque elevation, =0.25mm; 2=mild plaque elevation, =0.5 mm; 3=moderate plaque elevation, =0.75mm;4=severe plaque elevation, \>1 mm; Erythema: 0=no evidence of erythema, hyperpigmentation may be present, 1=faint erythema, 2=light red coloration, 3=moderate red coloration, 4=bright red coloration; Scaling: 0=no evidence of scaling, 1=minimal; occasional fine scale over less than 5% of lesion, 2=mild; fine scale dominates,3 =moderate; coarse scale predominates, 4 =severe; thick, scale predominates.Final IGA score of psoriasis was based upon average of induration,erythema and scaling scores assessed on a 5 point scale: cleared(0),minimal(1),mild(2),moderate (3), or severe (4).Higher score=more severe disease. Baseline: closest measurement taken prior to or at time of first study drug administration date.

    Time frame: Week 52

  33. Percentage of Participants Achieving IGA Score of 0 at Week 52 Among Participants Who Were IGA 0 Responders at Week 24

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

    Time frame: Week 52

  34. Percentage of Participants Achieving PASI 100 Response at Week 52 Among PASI 100 Responders at Week 24

    Percentage of participants achieving PASI 100 (100% improvement from baseline in PASI) response at Week 52 among PASI 100 responders at Week 24 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis.

    Time frame: Week 52

  35. Time to Loss of IGA Response of 0 or 1

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

    Time frame: Week 24 up to Week 52

  36. Adolescent Participants: Percentage of Participants With IGA Score of 0 or 1 and a >=2-grade Improvement From Baseline at Week 52

    IGA assesses participant's plaque psoriasis. Lesions were graded for induration,erythema and scaling,each using 5 point scale. Induration: 0=no evidence of plaque elevation, 1=minimal plaque elevation,=0.25mm; 2=mild plaque elevation,=0.5 mm; 3=moderate plaque elevation,= 0.75 mm; 4=severe plaque elevation, \>1mm; Erythema: 0=no evidence of erythema, hyperpigmentation may be present, 1=faint erythema, 2=light red coloration, 3=moderate red coloration, 4=bright red coloration; Scaling:0=no evidence of scaling, 1=minimal; occasional fine scale over less than 5% of lesion, 2=mild; fine scale dominates, 3=moderate; coarse scale predominates, 4=severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared(0), minimal(1), mild(2), moderate(3), or severe(4). Higher score=more severe disease. Baseline:closest measurement taken prior to or at time of first study drug administration date.

    Time frame: Week 52

  37. Adolescent Participants: Percentage of Participants Who Achieved PASI 75 Response at Week 52

    Percentage of participants who achieved PASI 75 (\>=75% improvement in PASI from baseline) response at Week 52 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. Baseline:closest measurement taken prior to or at time of first study drug administration date.

    Time frame: Week 52

  38. Adolescent Participants: Percentage of Participants Who Achieved PASI 90 Response at Week 52

    Percentage of participants who achieved PASI 90 (at least \>=90% improvement in PASI from baseline) response at Week 52 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. Baseline: closest measurement taken prior to or at time of first study drug administration date.

    Time frame: Week 52

  39. Number of Participants With Treatment-emergent Adverse Events (AEs)

    Time frame: From Week 0 up to Week 160

  40. Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)

    Time frame: From Week 0 up to Week 160

07

Results

Posted Jun 1, 2026

Participant flow

Placebo-controlled Period(PCP):Week 0-16
Participant flow — Placebo-controlled Period(PCP):Week 0-16
MilestonePlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Started228456
Completed213437
Not completed1519
Withdrew: Adverse event15
Withdrew: Lack of efficacy81
Withdrew: Lost to follow-up23
Withdrew: Physician decision10
Withdrew: Pregnancy01
Withdrew: Withdrawal by subject38
Withdrew: Non-compliance with study schedule01
After PCP: Weeks 16-24
Participant flow — After PCP: Weeks 16-24
MilestonePlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Started213437
Completed212436
Not completed11
Withdrew: Adverse event11
Randomized Withdrawal (RWD): Weeks 24-52
Participant flow — Randomized Withdrawal (RWD): Weeks 24-52
MilestonePlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Started212436
Responders (adults) re-randomized and treated with jnj-772421130168
Responders (adults) re-randomized to placebo0172
Non-responders (adults) and adolescents who were treated with jnj-77242113096
Completed199407
Not completed1329
Withdrew: Adverse event37
Withdrew: Lack of efficacy713
Withdrew: Pregnancy01
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject25
Withdrew: Non-compliance with study schedule11
Withdrew: Other01

Outcome measures

PrimaryPercentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16

IGA assesses participant's plaque psoriasis.Lesions were graded for induration,erythema and scaling, each using 5 point scale.Induration: 0=no evidence of plaque elevation,1=minimal plaque elevation,=0.25 millimeters(mm);2=mild plaque elevation,=0.5mm;3=moderate plaque elevation,=0.75 mm; 4=severe plaque elevation, greater than(\>)1 mm; Erythema:0=no evidence of erythema, hyperpigmentation may be present,1=faint erythema,2=light red coloration,3=moderate red coloration,4=bright red coloration; Scaling:0=no evidence of scaling, 1=minimal; occasional fine scale over \<5% of lesion, 2=mild; fine scale dominates,3=moderate; coarse scale predominates, 4=severe; thick, scale predominates. Final IGA score of psoriasis was based upon average of induration, erythema and scaling scores assessed on a 5 point scale:cleared(0),minimal(1), mild(2),moderate(3),or severe(4). Higher score=more severe disease. Baseline:closest measurement taken prior to or at time of first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16
Percentage of ParticipantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 168.364.7
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Cochran-Mantel-Haenszel · p = <0.001 · Treatment difference: 56.4 · 95% CI 50.4 to 61.7
PrimaryPercentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

Percentage of participants who achieved PASI 90 (at least 90% improvement from baseline in PASI score) response at Week 16 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 164.449.6
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Cochran-Mantel-Haenszel · p = <0.001 · Treatment difference: 45.1 · 95% CI 39.5 to 50.4
SecondaryPercentage of Participants Who Achieved IGA Score of 0 at Week 16

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeter (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved IGA Score of 0 at Week 16
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved IGA Score of 0 at Week 161.333.3
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Cochran-Mantel-Haenszel · p = <0.001 (p-value was adjusted for multiplicity.) · Treatment difference: 31.9 · 95% CI 27.2 to 36.6
SecondaryPercentage of Participants Who Achieved PASI 75 Response at Week 4

Percentage of participants who achieved PASI 75 (at least \>=75% improvement from baseline in PASI) response at Week 4 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 4
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PASI 75 Response at Week 4
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved PASI 75 Response at Week 42.214.9
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Cochran-Mantel-Haenszel · p = =0.002 (p-value was adjusted for multiplicity.) · Treatment difference: 12.7 · 95% CI 8.8 to 16.6
SecondaryPercentage of Participants Who Achieved PASI 90 Response at Week 8

Percentage of participants who achieved PASI 90 (at least \>=90% improvement from baseline in PASI) response at Week 8 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PASI 90 Response at Week 8
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved PASI 90 Response at Week 81.321.5
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Cochran-Mantel-Haenszel · p = <0.001 (p-value was adjusted for multiplicity.) · Treatment difference: 20.1 · 95% CI 15.9 to 24.5
SecondaryPercentage of Participants Who Achieved PASI 75 Response at Week 16

Percentage of participants who achieved PASI 75 (\>=75% improvement from baseline in PASI) response at Week 16 were reported.. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PASI 75 Response at Week 16
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved PASI 75 Response at Week 1611.069.1
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Cochran-Mantel-Haenszel · p = <0.001 (p-value was adjusted for multiplicity.) · Treatment difference: 58.1 · 95% CI 51.9 to 63.6
SecondaryPercentage of Participants Who Achieved PASI 100 Response at Week 16

Percentage of participants who achieved PASI 100 (100% improvement from baseline in PASI) response at Week 16 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PASI 100 Response at Week 16
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved PASI 100 Response at Week 160.427.0
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Cochran-Mantel-Haenszel · p = <0.001 (p-value was adjusted for multiplicity.) · Treatment difference: 26.5 · 95% CI 22.4 to 30.8
SecondaryPercentage of Participants Who Achieved Scalp Specific (ss)-IGA Score of 0 or 1 and >=2-Grade Improvement From Baseline at Week 16 Among Participants With a Baseline Ss-IGA Score >=2

The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions were assessed in terms of the clinical signs of redness, thickness, and scaliness, which are scored on a 5-point scale ranging from 0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, and 4 = severe disease. Higher score indicated severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Scalp Specific (ss)-IGA Score of 0 or 1 and >=2-Grade Improvement From Baseline at Week 16 Among Participants With a Baseline Ss-IGA Score >=2
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved Scalp Specific (ss)-IGA Score of 0 or 1 and >=2-Grade Improvement From Baseline at Week 16 Among Participants With a Baseline Ss-IGA Score >=215.072.3
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Cochran-Mantel-Haenszel · p = <0.001 (p-value was adjusted for multiplicity.) · Treatment difference: 57 · 95% CI 49.9 to 63.1
SecondaryPercentage of Participants Who Achieved Psoriasis Symptom and Signs Diary (PSSD) Symptom Score of 0 at Week 8 Among Participants With a Baseline PSSD Symptom Score >0

PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Symptom score was derived first by averaging the 5 weekly symptom item scores when at least 3 items are available (\>=50% of 5 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Psoriasis Symptom and Signs Diary (PSSD) Symptom Score of 0 at Week 8 Among Participants With a Baseline PSSD Symptom Score >0
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved Psoriasis Symptom and Signs Diary (PSSD) Symptom Score of 0 at Week 8 Among Participants With a Baseline PSSD Symptom Score >01.47.1
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Cochran-Mantel-Haenszel · p = =0.002 (p-value was adjusted for multiplicity.) · Treatment difference: 5.7 · 95% CI 2.0 to 8.9
SecondaryPercentage of Participants Who Achieved Psoriasis Symptom and Signs Diary (PSSD) Symptom Score of 0 at Week 16 Among Participants With a Baseline PSSD Symptom Score >0

PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Symptom score was derived first by averaging the 5 weekly symptom item scores when at least 3 items are available (\>=50% of 5 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Psoriasis Symptom and Signs Diary (PSSD) Symptom Score of 0 at Week 16 Among Participants With a Baseline PSSD Symptom Score >0
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved Psoriasis Symptom and Signs Diary (PSSD) Symptom Score of 0 at Week 16 Among Participants With a Baseline PSSD Symptom Score >01.020.1
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Cochran-Mantel-Haenszel · p = <0.001 (p-value was adjusted for multiplicity.) · Treatment difference: 19.2 · 95% CI 15.0 to 23.6
SecondaryPercentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Week 4 Among Participants With a Baseline PSSD Itch Score >=4

PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms(itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. PSSD itch item score over seven days was averaged into a weekly itch score, ranging from 0 to 10 with higher scores indicating severe disease. Baseline=closest measurement taken prior to or at time of first study drug administration date.

Time frame:
Week 4
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Week 4 Among Participants With a Baseline PSSD Itch Score >=4
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Week 4 Among Participants With a Baseline PSSD Itch Score >=45.119.1
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Cochran-Mantel-Haenszel · p = =0.002 (p-value was adjusted for multiplicity.) · Treatment difference: 14.1 · 95% CI 8.6 to 19.3
SecondaryPercentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Week 16 Among Participants With a Baseline PSSD Itch Score >=4

PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms(itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. PSSD itch item score over seven days was averaged into a weekly itch score, ranging from 0 to 10 with higher scores indicating severe disease. Baseline=closest measurement taken prior to or at time of first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Week 16 Among Participants With a Baseline PSSD Itch Score >=4
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Week 16 Among Participants With a Baseline PSSD Itch Score >=413.158.0
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Cochran-Mantel-Haenszel · p = <0.001 (p-value was adjusted for multiplicity.) · Treatment difference: 45.2 · 95% CI 37.5 to 52.0
SecondaryPercentage of Participants Who Achieved PASI 75 Response at Week 52 Among Participants Randomized at Week 24 and Were PASI 75 Responders at Week 24

Percentage of participants who achieved PASI-75 score (\>=75% improvement from baseline in PASI) at Week 52 among participants randomized at Week 24 and were PASI 75 responders at Week 24 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. Baseline=closest measurement taken prior to or at time of first study drug administration date.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PASI 75 Response at Week 52 Among Participants Randomized at Week 24 and Were PASI 75 Responders at Week 24
Percentage of participantsResponders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52)Responders: JNJ-77242113 200 mg (RWD Week 24-52)
Percentage of Participants Who Achieved PASI 75 Response at Week 52 Among Participants Randomized at Week 24 and Were PASI 75 Responders at Week 2429.589.4
Statistical analysis
  • Responders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52) vs Responders: JNJ-77242113 200 mg (RWD Week 24-52) · Cochran-Mantel-Haenszel · p = <0.001 (p-value was adjusted for multiplicity.) · Treatment difference: 59.6 · 95% CI 50.9 to 67.3
SecondaryPercentage of Participants Who Achieved PASI 90 Response at Week 52 Among Participants Randomized at Week 24 and Were PASI 90 Responders at Week 24

Percentage of participants who achieved PASI 90 (at least \>=90% improvement from baseline in PASI) response at Week 52 among participants randomized at Week 24 and were PASI 90 responders at Week 24 were reported. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. Baseline=closest measurement taken prior to or at time of first study drug administration date.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PASI 90 Response at Week 52 Among Participants Randomized at Week 24 and Were PASI 90 Responders at Week 24
Percentage of participantsResponders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52)Responders: JNJ-77242113 200 mg (RWD Week 24-52)
Percentage of Participants Who Achieved PASI 90 Response at Week 52 Among Participants Randomized at Week 24 and Were PASI 90 Responders at Week 2420.984.4
Statistical analysis
  • Responders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52) vs Responders: JNJ-77242113 200 mg (RWD Week 24-52) · Cochran-Mantel-Haenszel · p = <0.001 (p-value was adjusted for multiplicity.) · Treatment difference: 63.5 · 95% CI 53.1 to 72.0
SecondaryTime to Loss of PASI 75 Among Participants Randomized at Week 24 and Were PASI 75 Responders at Week 24

Time to loss of PASI 75 response was defined as time from re-randomization at Week 24 to visit of loss of PASI 75 response. Loss of PASI 75 response was defined as less than (\<)75% improvement in PASI from Week 24 up to Week 52 in an adult participant who had achieved \>=75% improvement in PASI from baseline at Week 24. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis.

Time frame:
Week 24 up to Week 52
Reported as:
Median · Weeks
Time to Loss of PASI 75 Among Participants Randomized at Week 24 and Were PASI 75 Responders at Week 24
WeeksResponders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52)Responders: JNJ-77242113 200 mg (RWD Week 24-52)
Time to Loss of PASI 75 Among Participants Randomized at Week 24 and Were PASI 75 Responders at Week 2416.9 (7.2 to 28.0)NA (NA to NA)
Statistical analysis
  • Responders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52) vs Responders: JNJ-77242113 200 mg (RWD Week 24-52) · Log Rank · p = <0.001 (p-value was adjusted for multiplicity.) · Hazard ratio (hr): 0.08 · 95% CI 0.05 to 0.13
SecondaryTime to Loss of PASI 90 Among Participants Randomized at Week 24 and Were PASI 90 Responders at Week 24

The time to loss of PASI 90 response was defined as the time from re-randomization at Week 24 to the visit of loss of PASI 90 response. Loss of PASI 90 response is defined as \<90% improvement in PASI from Week 24 up to Week 52 in an adult participant who had achieved \>=90% improvement in PASI from baseline at Week 24. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis.

Time frame:
Week 24 up to Week 52
Reported as:
Median · Weeks
Time to Loss of PASI 90 Among Participants Randomized at Week 24 and Were PASI 90 Responders at Week 24
WeeksResponders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52)Responders: JNJ-77242113 200 mg (RWD Week 24-52)
Time to Loss of PASI 90 Among Participants Randomized at Week 24 and Were PASI 90 Responders at Week 2410.1 (5.4 to 25.2)NA (NA to NA)
Statistical analysis
  • Responders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52) vs Responders: JNJ-77242113 200 mg (RWD Week 24-52) · Log Rank · p = <0.001 (p-value was adjusted for multiplicity.) · Hazard ratio (hr): 0.13 · 95% CI 0.08 to 0.20
SecondaryChange From Baseline in Body Surface Area (BSA) at Week 16

A BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using hand print method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1% BSA. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Percentage of BSA
Change From Baseline in Body Surface Area (BSA) at Week 16
Percentage of BSAPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Change From Baseline in Body Surface Area (BSA) at Week 16-4.45 ± 12.118-18.77 ± 15.628
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Least square (ls) mean difference: -15.6 · 95% CI -17.29 to -13.95
SecondaryChange From Baseline in PASI Total Score at Week 16

Change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Units on a scale
Change From Baseline in PASI Total Score at Week 16
Units on a scalePlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Change From Baseline in PASI Total Score at Week 16-4.94 ± 8.088-15.65 ± 8.602
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -11.4 · 95% CI -12.49 to -10.41
SecondaryPercent Change From Baseline in PASI Total Score at Week 16

Percent change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in PASI Total Score at Week 16
Percent changePlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percent Change From Baseline in PASI Total Score at Week 16-23.32 ± 37.129-78.70 ± 28.893
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -55.1 · 95% CI -60.21 to -50.09
SecondaryPercentage of Participants Who Achieved Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 and a >=2-Grade Improvement in Genital Psoriasis From Baseline at Week 16 Among Participants With a Baseline sPGA-G Score >=2

Percentage of participants achieving a sPGA-G Score of 0 or 1 and at least a 2-grade improvement in genital psoriasis from baseline at Week 16 among participants with a baseline sPGA-G score \>=2 was reported. The sPGA-G was a 6-point scale to assess the severity of genital psoriasis at a given time point. The sPGA-G evaluates erythema, plaque elevation, and scale of genital psoriatic lesions. The severity of genital psoriasis was assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), and very severe (5). Higher score indicates more severity. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 and a >=2-Grade Improvement in Genital Psoriasis From Baseline at Week 16 Among Participants With a Baseline sPGA-G Score >=2
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 and a >=2-Grade Improvement in Genital Psoriasis From Baseline at Week 16 Among Participants With a Baseline sPGA-G Score >=238.170.5
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Treatment difference: 35.6 · 95% CI 20.7 to 49.0
SecondaryPercentage of Participants Achieving a Physician's Global Assessment of Hands and Feet (Hf-PGA) Score of 0 or 1 and at Least a 2-grade Improvement at Week 16 Among Participants With a Baseline Hf-PGA Score >=2

Percentage of participants achieving a hf-PGA score of 0 or 1 and at least a 2-grade improvement at Week 16 among participants with a baseline hf-PGA score \>=2 was reported. The hf-PGA assesses the severity of hand and foot psoriasis using a 5-point scale to score the plaques on the hands and feet. hf-PFA was categorized from 0 to 4 where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Higher score indicates more severity. Meeting the hf-PGA 0 or 1 criteria defined as having an hf-PGA score of clear (0) or almost clear (1) and a \>=2-grade improvement from baseline. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Physician's Global Assessment of Hands and Feet (Hf-PGA) Score of 0 or 1 and at Least a 2-grade Improvement at Week 16 Among Participants With a Baseline Hf-PGA Score >=2
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Achieving a Physician's Global Assessment of Hands and Feet (Hf-PGA) Score of 0 or 1 and at Least a 2-grade Improvement at Week 16 Among Participants With a Baseline Hf-PGA Score >=221.673.0
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Treatment difference: 50.6 · 95% CI 38.6 to 60.7
SecondaryPercent Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 16 Among Participants With Baseline mNAPSI Score >0

The mNAPSI was an index used for assessing and grading the severity of nail psoriasis. Each of the participant's ten fingernails are evaluated on 7 features. The first three features are each scored from 0 to 3 in severity and were 1 = onycholysis and oil-drop dyschromia, 2 = pitting, and 3 = nail plate crumbling. The next four features was each scored 0 (absent) or 1 (present), and are (1) leukonychia, (2) splinter hemorrhages (3) nail bed hyperkeratosis, and (4) red spots in the lunula. Each fingernail is rated for the presence and severity of seven features to give a total fingernail score of 0-13 (0= no involvement, 13 = greatest involvement). The total mNAPSI score is the sum of the 10 fingernail scores (range 0-130; 0= no involvement, 130= greatest involvement). The higher the score the more severe the nail bed psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 16 Among Participants With Baseline mNAPSI Score >0
Percent changePlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percent Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 16 Among Participants With Baseline mNAPSI Score >01.7 ± 133.97-37.9 ± 105.42
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -41.3 · 95% CI -69.67 to -12.84
SecondaryPercentage of Participants Who Achieved Fingernail Physician's Global Assessment (f-PGA) Score of 0 or 1 at Week 16 Among Participants With a Baseline f-PGA Score >=2

Percentage of participants who achieved f-PGA score of 0 or 1 at Week 16 was reported. f-PGA 0 or 1 criteria was defined as an f-PGA score of clear (0) or minimal (1). The f-PGA is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe. The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4= severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Fingernail Physician's Global Assessment (f-PGA) Score of 0 or 1 at Week 16 Among Participants With a Baseline f-PGA Score >=2
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Who Achieved Fingernail Physician's Global Assessment (f-PGA) Score of 0 or 1 at Week 16 Among Participants With a Baseline f-PGA Score >=221.250.4
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Treatment difference: 30.1 · 95% CI 16.4 to 42.0
SecondaryChange From Baseline in PSSD Symptom Score at Week 16

PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms(itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Symptom score was derived by averaging the 5 weekly symptom item scores when at least 3 items are available (\>=50% of 5 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Units on a scale
Change From Baseline in PSSD Symptom Score at Week 16
Units on a scalePlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Change From Baseline in PSSD Symptom Score at Week 16-5.2 ± 24.10-33.8 ± 25.13
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -27.1 · 95% CI -30.58 to -23.66
SecondaryChange From Baseline in PSSD Sign Score at Week 16

PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms(itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Sign score was derived by averaging the 6 weekly sign item scores when at least 3 items are available (\>=50% of 6 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Units on a scale
Change From Baseline in PSSD Sign Score at Week 16
Units on a scalePlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Change From Baseline in PSSD Sign Score at Week 16-7.4 ± 23.46-37.2 ± 24.04
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -29.3 · 95% CI -32.72 to -25.79
SecondaryPercentage of Participants Achieving PSSD Sign Score of 0 at Week 16 Among Participants With Baseline PSSD Sign Score >0

PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 24-hour recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Each individual item score over seven days was averaged into a weekly item score. Sign score was derived by averaging the 6 weekly sign item scores when at least 3 items are available (\>=50% of 6 items). Average score was then multiplied by 10 to convert into 0-100 scoring (0-least severe, 100-most severe). The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving PSSD Sign Score of 0 at Week 16 Among Participants With Baseline PSSD Sign Score >0
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Achieving PSSD Sign Score of 0 at Week 16 Among Participants With Baseline PSSD Sign Score >0016.6
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Treatment difference: 16.7 · 95% CI 13.2 to 20.6
SecondaryPercentage of Participants Achieving Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16 Among Participants With Baseline GenPS-SFQ Item 2 Score >=2 and a Baseline sPGA-G Score >=3

Percentage of participants achieving GenPs-SFQ Item 2 score of 0 or 1 at Week 16 among participants with baseline GenPS-SFQ Item 2 score \>=2 and a baseline sPGA-G score \>=3 was reported. GenPs-SFQ was a 2-item participant-reported instrument used to assess the impact of genital psoriasis on the frequency of sexual activity in the last 7 days. Item 1 assesses overall frequency of sexual activity in the last 7 days (none/ zero, once, or 2 or more times), and item 2 assesses how frequently genital psoriasis symptoms have limited the frequency of sexual activity in the last 7 days (0 = never, 1 = rarely, 2 = sometimes, 3 = often, or 4 = always). Lower scores of item 2 indicated less limitation of sexual activity due to genital psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16 Among Participants With Baseline GenPS-SFQ Item 2 Score >=2 and a Baseline sPGA-G Score >=3
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Achieving Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16 Among Participants With Baseline GenPS-SFQ Item 2 Score >=2 and a Baseline sPGA-G Score >=346.256.8
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Treatment difference: 10.4 · 95% CI -20.2 to 39.3
SecondaryPercentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16 Among Participants With a Baseline DLQI Score >1

The DLQI was a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It was a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, could be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Each question was scored on a 4-point scale of 0 to 3 (0 = not at all, 1 = a little; 2 = a lot; or 3 = very much, where higher score indicated more impact on QoL). The total score was sum of scores from all 10 questions and it ranged from 0 (not at all) to 30 (very much), with a higher score indicating greater impact on HRQoL. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16 Among Participants With a Baseline DLQI Score >1
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16 Among Participants With a Baseline DLQI Score >111.052.0
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Treatment difference: 41.1 · 95% CI 34.1 to 47.3
SecondaryChange From Baseline in Total DLQI Score at Week 16

Change from baseline in total DLQI score at Week 16 was reported. The DLQI was a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It was a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, could be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Each question was scored on a 4-point scale of 0 to 3 (0 = not at all, 1 = a little; 2 = a lot; or 3 = very much, where higher score indicated more impact on QoL). The total score was sum of scores from all 10 questions and it ranged from 0 (not at all) to 30 (very much), with a higher score indicating greater impact on HRQoL. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Unit on a scale
Change From Baseline in Total DLQI Score at Week 16
Unit on a scalePlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Change From Baseline in Total DLQI Score at Week 16-2.7 ± 6.32-8.5 ± 6.95
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -5.5 · 95% CI -6.29 to -4.67
SecondaryAdult Participants: Change From Baseline in Domain Scores of the Patient-reported Outcomes Measurement Information System-29 (PROMIS-29) Score at Week 16

PROMIS-29, 29-item generic HRQoL survey, assesses each 7 PROMIS domains (depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; ability to participate in social roles and activities) with 4 questions and pain intensity. Questions ranked on 5-point Likert Scale (1=never, 2=rarely, 3=sometimes, 4=often and 5=always). Pain intensity was rated on 11-point scale (0=no pain; 10=worst imaginable pain). Higher score= worst pain. Each domain included 4 items, plus a single pain intensity item totaling 29 items. Raw score of each PROMIS domain was converted into a standardized score with mean of 50; standard deviation (SD) of 10 (T-Score). Higher PROMIS T score=more of concept being measured that is, higher scores in anxiety, depression, fatigue, pain interference, sleep disturbance= worse symptoms, higher scores in physical function, social roles=better functioning. Baseline: closest measurement taken prior to/at the time of first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Unit on a scale
Adult Participants: Change From Baseline in Domain Scores of the Patient-reported Outcomes Measurement Information System-29 (PROMIS-29) Score at Week 16
Unit on a scalePlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Physical function2.0 ± 6.772.9 ± 6.48
Anxiety-2.9 ± 6.63-5.1 ± 8.09
Depression-2.0 ± 6.68-3.7 ± 6.70
Fatigue-2.4 ± 7.59-4.6 ± 8.33
Pain interference-3.3 ± 7.95-7.1 ± 8.42
Sleep disturbance-1.5 ± 6.60-3.3 ± 6.95
Social roles and activity1.8 ± 8.124.9 ± 7.23
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls means difference: 0.9 · 95% CI 0.07 to 1.76
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -1.3 · 95% CI -2.27 to -0.40
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -1.2 · 95% CI -2.00 to -0.40
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -1.4 · 95% CI -2.55 to -0.22
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -3.5 · 95% CI -4.59 to -2.46
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -1.3 · 95% CI -2.32 to -0.29
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: 2.5 · 95% CI 1.58 to 3.44
SecondaryAdolescent Participants: Percentage of Participants Achieving Children's Dermatology Life Quality Index (CDLQI) Score of 0 or 1 at Week 16 Among Participants With a Baseline CDLQI Score >1

The CDLQI was an adapted version of the DLQI for the pediatric population and was utilized in the adolescent population in this study. The CDLQI is a 10-item instrument that has 4 item response options and a recall period of 1 week. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of questions 1-10 and ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children. The instrument is designed for use in children, is self-explanatory and can be simply handed to the participant who asked to fill it in with the help of the child's parent or caregiver. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Adolescent Participants: Percentage of Participants Achieving Children's Dermatology Life Quality Index (CDLQI) Score of 0 or 1 at Week 16 Among Participants With a Baseline CDLQI Score >1
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Adolescent Participants: Percentage of Participants Achieving Children's Dermatology Life Quality Index (CDLQI) Score of 0 or 1 at Week 16 Among Participants With a Baseline CDLQI Score >110.567.5
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Treatment difference: 54 · 95% CI 31.3 to 71.6
SecondaryAdolescent Participants: Change From Baseline in CDLQI at Week 16

The CDLQI was an adapted version of the DLQI for the pediatric population and was utilized in the adolescent population in this study. The CDLQI is a 10-item instrument that has 4 item response options and a recall period of 1 week. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of questions 1-10 and ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children. The instrument is designed for use in children, is self-explanatory and can be simply handed to the participant who asked to fill it in with the help of the child's parent or caregiver. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Units on a scale
Adolescent Participants: Change From Baseline in CDLQI at Week 16
Units on a scalePlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Adolescent Participants: Change From Baseline in CDLQI at Week 16-2.3 ± 5.30-5.4 ± 6.02
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -2.8 · 95% CI -4.13 to -1.41
SecondaryAdolescent Participants: Change From Baseline in Domain Scores of the PROMIS-25 Pediatric Score at Week 16

The PROMIS-25 was utilized in the adolescent population and is a 25-item generic HRQoL survey. Six PROMIS domains (physical function mobility, anxiety, depressive symptoms, fatigue, peer relationships, pain interference) are each assessed with 4 questions. Questions ranked on 5-point Likert Scale (1=never, 2=rarely, 3=sometimes, 4=often, 5=always). Higher score=worst pain. Raw scores for each domain were converted to T-scores using standardized score with a mean of 50 and a standard deviation (SD) of 10 with an observed range 20 to 80. For anxiety, depressive symptoms, fatigue, and pain interference, a negative change indicates an improvement while for physical function mobility and peer relationships, a positive change indicates an improvement. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Unit on a scale
Adolescent Participants: Change From Baseline in Domain Scores of the PROMIS-25 Pediatric Score at Week 16
Unit on a scalePlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Anxiety-6.2 ± 8.21-4.8 ± 7.95
Depressive symptoms-1.8 ± 6.76-3.8 ± 6.74
Fatigue-6.2 ± 8.14-5.7 ± 7.55
Pain interference-1.1 ± 4.85-4.1 ± 7.16
Physical function mobility4.1 ± 7.483.7 ± 6.99
Peer relationships-2.4 ± 13.05-0.2 ± 14.01
Statistical analysis
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: 0.7 · 95% CI -2.46 to 3.78
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -0.9 · 95% CI -3.60 to 1.82
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: 0 · 95% CI -3.03 to 3.04
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: -2.2 · 95% CI -4.40 to 0.05
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: 1.7 · 95% CI -0.45 to 3.77
  • Placebo to JNJ-77242113 200 mg vs JNJ-77242113 200 mg · Ls mean difference: 0.3 · 95% CI -6.60 to 7.12
SecondaryPercentage of Participants Who Achieved an IGA Score of 0 or 1 and >=2-Grade Improvement From Baseline at Week 52

IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0=no evidence of plaque elevation, 1=minimal plaque elevation, =0.25mm; 2=mild plaque elevation, =0.5 mm; 3=moderate plaque elevation, =0.75mm;4=severe plaque elevation, \>1 mm; Erythema: 0=no evidence of erythema, hyperpigmentation may be present, 1=faint erythema, 2=light red coloration, 3=moderate red coloration, 4=bright red coloration; Scaling: 0=no evidence of scaling, 1=minimal; occasional fine scale over less than 5% of lesion, 2=mild; fine scale dominates,3 =moderate; coarse scale predominates, 4 =severe; thick, scale predominates.Final IGA score of psoriasis was based upon average of induration,erythema and scaling scores assessed on a 5 point scale: cleared(0),minimal(1),mild(2),moderate (3), or severe (4).Higher score=more severe disease. Baseline: closest measurement taken prior to or at time of first study drug administration date.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved an IGA Score of 0 or 1 and >=2-Grade Improvement From Baseline at Week 52
Percentage of participantsResponders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52)Responders: JNJ-77242113 200 mg (RWD Week 24-52)
Percentage of Participants Who Achieved an IGA Score of 0 or 1 and >=2-Grade Improvement From Baseline at Week 5223.382.0
Statistical analysis
  • Responders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52) vs Responders: JNJ-77242113 200 mg (RWD Week 24-52) · Treatment difference: 60.2 · 95% CI 50.8 to 68.3
SecondaryPercentage of Participants Achieving IGA Score of 0 at Week 52 Among Participants Who Were IGA 0 Responders at Week 24

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving IGA Score of 0 at Week 52 Among Participants Who Were IGA 0 Responders at Week 24
Percentage of participantsResponders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52)Responders: JNJ-77242113 200 mg (RWD Week 24-52)
Percentage of Participants Achieving IGA Score of 0 at Week 52 Among Participants Who Were IGA 0 Responders at Week 2410.870.2
Statistical analysis
  • Responders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52) vs Responders: JNJ-77242113 200 mg (RWD Week 24-52) · Treatment difference: 59.3 · 95% CI 46.7 to 69.8
SecondaryPercentage of Participants Achieving PASI 100 Response at Week 52 Among PASI 100 Responders at Week 24

Percentage of participants achieving PASI 100 (100% improvement from baseline in PASI) response at Week 52 among PASI 100 responders at Week 24 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving PASI 100 Response at Week 52 Among PASI 100 Responders at Week 24
Percentage of participantsResponders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52)Responders: JNJ-77242113 200 mg (RWD Week 24-52)
Percentage of Participants Achieving PASI 100 Response at Week 52 Among PASI 100 Responders at Week 249.874.0
Statistical analysis
  • Responders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52) vs Responders: JNJ-77242113 200 mg (RWD Week 24-52) · Treatment difference: 64.8 · 95% CI 51.9 to 75.1
SecondaryTime to Loss of IGA Response of 0 or 1

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

Time frame:
Week 24 up to Week 52
Reported as:
Median · Weeks
Time to Loss of IGA Response of 0 or 1
WeeksResponders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52)Responders: JNJ-77242113 200 mg (RWD Week 24-52)
Time to Loss of IGA Response of 0 or 110.1 (5.1 to 26.2)NA (26.8 to NA)
Statistical analysis
  • Responders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52) vs Responders: JNJ-77242113 200 mg (RWD Week 24-52) · Hazard ratio (hr): 0.15 · 95% CI 0.10 to 0.23
SecondaryAdolescent Participants: Percentage of Participants With IGA Score of 0 or 1 and a >=2-grade Improvement From Baseline at Week 52

IGA assesses participant's plaque psoriasis. Lesions were graded for induration,erythema and scaling,each using 5 point scale. Induration: 0=no evidence of plaque elevation, 1=minimal plaque elevation,=0.25mm; 2=mild plaque elevation,=0.5 mm; 3=moderate plaque elevation,= 0.75 mm; 4=severe plaque elevation, \>1mm; Erythema: 0=no evidence of erythema, hyperpigmentation may be present, 1=faint erythema, 2=light red coloration, 3=moderate red coloration, 4=bright red coloration; Scaling:0=no evidence of scaling, 1=minimal; occasional fine scale over less than 5% of lesion, 2=mild; fine scale dominates, 3=moderate; coarse scale predominates, 4=severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared(0), minimal(1), mild(2), moderate(3), or severe(4). Higher score=more severe disease. Baseline:closest measurement taken prior to or at time of first study drug administration date.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Adolescent Participants: Percentage of Participants With IGA Score of 0 or 1 and a >=2-grade Improvement From Baseline at Week 52
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Adolescent Participants: Percentage of Participants With IGA Score of 0 or 1 and a >=2-grade Improvement From Baseline at Week 5290.981.8
SecondaryAdolescent Participants: Percentage of Participants Who Achieved PASI 75 Response at Week 52

Percentage of participants who achieved PASI 75 (\>=75% improvement in PASI from baseline) response at Week 52 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. Baseline:closest measurement taken prior to or at time of first study drug administration date.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Adolescent Participants: Percentage of Participants Who Achieved PASI 75 Response at Week 52
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Adolescent Participants: Percentage of Participants Who Achieved PASI 75 Response at Week 5290.995.5
SecondaryAdolescent Participants: Percentage of Participants Who Achieved PASI 90 Response at Week 52

Percentage of participants who achieved PASI 90 (at least \>=90% improvement in PASI from baseline) response at Week 52 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. Baseline: closest measurement taken prior to or at time of first study drug administration date.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Adolescent Participants: Percentage of Participants Who Achieved PASI 90 Response at Week 52
Percentage of participantsPlacebo to JNJ-77242113 200 mgJNJ-77242113 200 mg
Adolescent Participants: Percentage of Participants Who Achieved PASI 90 Response at Week 5277.386.4
SecondaryNumber of Participants With Treatment-emergent Adverse Events (AEs)
Time frame:
From Week 0 up to Week 160

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment-emergent Serious Adverse Events (SAEs)
Time frame:
From Week 0 up to Week 160

Results for this outcome have not been posted.

Adverse events

Collected over Placebo-controlled period (PCP): Weeks 0-16; After PCP: Weeks 16-24; Randomized Withdrawal (RWD) period: Weeks 24-52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (PCP Week 0-16)0/228 (0%)6/228 (2.6%)31/228 (13.6%)
JNJ-77242113 200 mg (PCP Week 0-16)0/456 (0%)6/456 (1.3%)59/456 (12.9%)
Placebo to JNJ-77242113 200 mg (After PCP Week 16-24)0/213 (0%)1/213 (0.5%)11/213 (5.2%)
JNJ-77242113 200 mg (After PCP Week 16-24)0/437 (0%)5/437 (1.1%)17/437 (3.9%)
Placebo to JNJ-77242113 200 mg (Week 24-52)0/212 (0%)3/212 (1.4%)39/212 (18.4%)
Responders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52)0/172 (0%)2/172 (1.2%)10/172 (5.8%)
Responders: JNJ-77242113 200 mg (RWD Week 24-52)0/168 (0%)3/168 (1.8%)29/168 (17.3%)
JNJ-77242113 200 mg (Week 24-52)0/96 (0%)2/96 (2.1%)20/96 (20.8%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPlacebo (PCP Week 0-16)JNJ-77242113 200 mg (PCP Week 0-16)Placebo to JNJ-77242113 200 mg (After PCP Week 16-24)JNJ-77242113 200 mg (After PCP Week 16-24)Placebo to JNJ-77242113 200 mg (Week 24-52)Responders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52)Responders: JNJ-77242113 200 mg (RWD Week 24-52)JNJ-77242113 200 mg (Week 24-52)
SyncopeNervous system disorders0/2280/4560/2130/4370/2120/1720/1682/96
Acute Cholecystitis NecroticHepatobiliary disorders0/2280/4560/2130/4370/2120/1721/1680/96
ArthritisMusculoskeletal and connective tissue disorders0/2280/4560/2130/4370/2120/1721/1680/96
Aortic AneurysmVascular disorders0/2280/4560/2130/4370/2120/1721/1680/96
Anal FistulaGastrointestinal disorders0/2280/4560/2130/4370/2121/1720/1680/96
Varicose VeinVascular disorders0/2280/4560/2130/4370/2121/1720/1680/96
DiverticulitisInfections and infestations0/2280/4560/2130/4371/2120/1720/1680/96
Lumbar Vertebral FractureInjury, poisoning and procedural complications0/2280/4560/2130/4371/2120/1720/1680/96
Status MigrainosusNervous system disorders0/2280/4560/2130/4371/2120/1720/1680/96
PsoriasisSkin and subcutaneous tissue disorders1/2280/4561/2130/4370/2120/1720/1680/96
Most frequent other events
Most frequent other events
EventPlacebo (PCP Week 0-16)JNJ-77242113 200 mg (PCP Week 0-16)Placebo to JNJ-77242113 200 mg (After PCP Week 16-24)JNJ-77242113 200 mg (After PCP Week 16-24)Placebo to JNJ-77242113 200 mg (Week 24-52)Responders: JNJ-77242113 200 mg to Placebo (RWD Week 24-52)Responders: JNJ-77242113 200 mg (RWD Week 24-52)JNJ-77242113 200 mg (Week 24-52)
NasopharyngitisInfections and infestations15/22831/4565/21311/43720/2126/17221/16814/96
Upper Respiratory Tract InfectionInfections and infestations16/22830/4566/2136/43720/2124/1729/1688/96

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo to JNJ-77242113 200 mgJNJ-77242113 200 mgTotal
Mean43.2 ± 16.5742.4 ± 16.2942.6 ± 16.38
Sex: Female, Male
Sex: Female, Male(Participants)Placebo to JNJ-77242113 200 mgJNJ-77242113 200 mgTotal
Female72165237
Male156291447
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo to JNJ-77242113 200 mgJNJ-77242113 200 mgTotal
Hispanic or Latino276188
Not Hispanic or Latino199386585
Unknown or Not Reported2911
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo to JNJ-77242113 200 mgJNJ-77242113 200 mgTotal
American Indian or Alaska Native101
Asian57110167
Native Hawaiian or Other Pacific Islander022
Black or African American268
White165329494
More than one race011
Unknown or Not Reported3811
Region of Enrollment
Region of Enrollment(Participants)Placebo to JNJ-77242113 200 mgJNJ-77242113 200 mgTotal
Australia4610
Canada274471
China3467101
Germany3764101
Hungary71219
Italy011
Japan527
Korea, Republic of279
Poland43107150
Spain51318
Taiwan51621
Turkey6511
United Kingdom7815
United States3985124
Argentina71926
08

Study locations

170 sites

Showing the first 100 of 170 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bissonnette R, Soung J, Hebert AA, Pink AE, Pinter A, Moore AY, Shi Y, Wang WH, Toth DP, Miller-Kassamali M, Cafone J, Jiang J, Li S, DeKlotz CMC, Nunes F, Lebwohl MG. Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. N Engl J Med. 2025 Nov 6;393(18):1784-1795. doi: 10.1056/NEJMoa2504187. PubMed 41191940 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jul 2024, 9 months.

Results were first posted in Jun 2026, 1 year 10 months after primary completion. A results delay was requested in Jul 2025.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2023
First posted
Oct 23, 2023
StartActual
Oct 12, 2023
Primary completionActual
Jul 29, 2024
CompletionEst.
Apr 6, 2027
Results delay requested
Jul 28, 2025
Results first posted
Jun 1, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (1 Australia, 1 Canada, 1 United States, 1 Japan)
  • Veracity Clinical Research · Greenslopes, Australia
  • Avenue Research Group · Toronto, Canada
  • Pharmacology Translational Unit PTU Fairborn LLC · Fairborn, United States
  • Teikyo University Hospital · tabashi City, Japan
Show 4 removed
  • Veracity Clinical Research · Woolloongabba, Australia
  • Toronto Research Centre · Toronto, Canada
  • Dermatologists of Central States LLC · Fairborn, United States
  • Teikyo University Hospital · Itabashi Ku, Japan
across 2 updates, Sep 28, 2026 – Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 United States, 1 Japan)
    • Pharmacology Translational Unit PTU Fairborn LLC · Fairborn, United States
    • Teikyo University Hospital · tabashi City, Japan
    Show 2 removed
    • Dermatologists of Central States LLC · Fairborn, United States
    • Teikyo University Hospital · Itabashi Ku, Japan
    + 1 other change: verification date
  2. Sep 28, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 Australia, 1 Canada)
    • Veracity Clinical Research · Greenslopes, Australia
    • Avenue Research Group · Toronto, Canada
    Show 2 removed
    • Veracity Clinical Research · Woolloongabba, Australia
    • Toronto Research Centre · Toronto, Canada
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06095115
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Oct 12, 2023
Primary completion
Jul 29, 2024
Completion
Apr 6, 2027 (estimated)
Results posted
Jun 1, 2026
Last update
Nov 4, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icotrokinra

Start the discussion